Tag : Phase II clinical trial of ZYIL1

Zydus Lifesciences initiates Phase II clinical trial of ZYIL1, a novel oral NLRP3 inflammasome inhibitor in patients with Amyotrophic Lateral Sclerosis (ALS)

NewsmantraOctober 25, 2023

by NewsmantraOctober 25, 20230

The Phase 2 clinical trial will assess the safety and efficacy of ZYIL1 in Amyotrophic...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More